



SHALU 54171520162

PID NO: P11171323900  
Age: 43 Year(s) Sex: Male

Reference:

Sample Collected At:  
METROPOLIS HEALTHCARE LTD  
DELHI  
F-2, Block -B1 ( Ground Floor ) Mohan  
Co-oprative Industrial Estate Mathura  
Road, New Delhi -110044  
Zone: OUT-01(OS)110044

VID: 11177356020

Registered On:  
07/02/2018 07:31 PM  
Collected On:  
05/02/2018  
Reported On:  
12/02/2018 05:02 PM

**BCR-ABL IS (International Scale) Transcript fusion Quantification**

**Test Principle** : Real Time PCR  
**Equipment** : Rotor Gene 3000 from Corbett Research, Australia  
**Specimen** : Blood

**Result :**

<b>M-BCR-ABL IS count %</b>	<b>0.4382 %</b>
<b>ABL (Control Gene)</b>	<b>42353 copies</b>

**Result Interpretation:**

- The international reporting scale (IS) has been established which expresses detectable disease as a percentage (0.1 % is corresponds to MMR) and is essentially identical to that used in the IRIS trial to achieve Major molecular response (MMR).
- BCR-ABL transcript quantification is expressed as a % of the control gene i.e., ABL. The sample showing amplification curve for both BCR/ABL transcript fusion gene (FG) and (CG) are considered as positive for the test and are reported as a % expression of BCR/ABL over ABL.
- In the absence of amplification curve for the CG or copies < 10000, the test is reported as invalid, denoting degradation of RNA.
- This test is directed for the quantification of Major breakpoint at e14a2 and e13a2 corresponding p210 transcript, which is found in 95 % of CML patients.

**Reference Range of Major Molecular Response (MMR) Status:**

IS BCR-ABL/ABL %	Log Reduction	Response
IS BCR-ABL/ABL% < 0.001	5.0	Deep Molecular Response (DMR)
IS BCR-ABL/ABL% < 0.0032	4.5	Deep Molecular Response (DMR)
IS BCR-ABL/ABL% < 0.01	4	Deep Molecular Response (DMR)
IS BCR-ABL/ABL% < 0.1	3	Major Molecular Response (MMR)
0.1 < IS BCR-ABL/ABL% < 0.15	-	Around the MMR cut –off
IS BCR-ABL/ABL% > 0.15	-	No Major molecular Response

**Dr. Niranjana Patil**  
Microbiologist  
(MD,MICROBIOLOGY)

SHALU 54171520162

**Reference:**

**VID: 11177356020**

PID NO: P11171323900

Age: 43 Year(s) Sex: Male

Sample Collected At:  
METROPOLIS HEALTHCARE LTD  
DELHI  
F-2, Block -B1 ( Ground Floor ) Mohan  
Co-oprative Industrial Estate Mathura  
Road, New Delhi -110044  
Zone: OUT-01(OS)110044

Registered On:  
07/02/2018 07:31 PM  
Collected On:  
05/02/2018  
Reported On:  
12/02/2018 05:02 PM

**Clinical Background:**

- Quantitative analysis of BCR/ABL transcript level by real time PCR should ideally be performed before the start of the therapy in order to determine the baseline value and for minimal residual disease (MRD) estimation.
- Since the introduction of BCR-ABL kinase inhibitor therapy, molecular monitoring after achieving complete cytogenetic response (CCR) post- initiation therapy has become particularly relevant & crucial.
- The BCR-ABL gene translocation or t(9;22) is found in more than 95% CML patients, 5% of paediatric ALL-B CALLA positive and 15-30% of adult ALL-B CALLA positive patients. This genetic aberration is a balanced reciprocal translocation between ABL gene on chromosome 9 and BCR gene on chromosome 22. This test is performed for the quantitative detection and differentiation of BCR-ABL fusion gene transcripts, Major (M), minor (m) and micro in bone marrow or peripheral blood samples of ALL or CML using real time PCR. Follow-up is recommended, if clinically indicated. A repeat testing after 6 months is additionally recommended.
- The lower limit of BCR-ABL transcript detection in the assay is dependent on the quality of RNA obtained and the cellularity of the sample. Since genetic variation and other problems can affect the accuracy of PCR based testing, the result should always be interpreted in light of clinical data.


**Limitation of Assay:**

- Other Transcripts p230 and p190 cannot be detected by this assay.
- PCR is a highly sensitive method; common reasons for paradoxical results are contamination during specimen collection, selection of inappropriate specimens and inherent PCR inhibitors in the specimen.

**Reference:**

- BACCARANI et al., European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, BLOOD, 8 AUGUST 2013, VOLUME 122, NUMBER 6
- ChaoJie Zhen and Y. Lynn Wang, Molecular Monitoring of Chronic Myeloid Leukemia: International Standardization of BCR-ABL1 Quantitation, J Mol Diagn 2013, 15: 556e564

-- End of Report --



**Dr. Niranjana Patil**  
Microbiologist  
(MD, MICROBIOLOGY)